 Diabetes Obes Metab. 2016;18(3):203–16. 31. Leiter LA, Carr MC, Stewart M, et al. Efﬁcacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a ran- domized phase III study. Diabetes Care. 2014;37(10):2723–30. 32. Davies MJ, Bain SC, Atkin SL, et al. Efﬁcacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222–30. 33. Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA, LEADER Steering Committee; LEADER Trial Investiga- tors. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER ran- domized trial. Diabetes Care. 2017;40(7):966–72. 34. Jensen L, Kupcova V, Arold G, et al. Pharmacokinetics and toler- ability of semaglutide in people with hepatic impairment. Diabetes Obes Metab Epub. 2017. https://doi.org/10.1111/dom.13186. 1580 C. Granhall et al.